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Abstract: The skeletal system, comprising bones, ligaments, cartilage and their connective tissues,
is critical for the structure and support of the body. Diseases that affect the skeletal system can be
difficult to treat, mainly because of the avascular cartilage region. Targeting drugs to the site of
action can not only increase efficacy but also reduce toxicity. Bone-targeting drugs are designed with
either of two general targeting moieties, aimed at the entire skeletal system or a specific cell type.
Most bone-targeting drugs utilize an affinity to hydroxyapatite, a major component of the bone matrix
that includes a high concentration of positively-charged Ca2+. The strategies for designing such
targeting moieties can involve synthetic and/or biological components including negatively-charged
amino acid peptides or bisphosphonates. Efficient delivery of bone-specific drugs provides significant
impact in the treatment of skeletal related disorders including infectious diseases (osteoarthritis,
osteomyelitis, etc.), osteoporosis, and metabolic skeletal dysplasia. Despite recent advances, however,
both delivering the drug to its target without losing activity and avoiding adverse local effects remain
a challenge. In this review, we investigate the current development of bone-targeting moieties,
their efficacy and limitations, and discuss future directions for the development of these specific
targeted treatments.
Keywords: bone targeting drugs; osteoporosis; metabolic skeletal dysplasia; bisphosphonates;
nanoparticles
1. Overview
More than 350 disorders encompass the collective group of skeletal dysplasias. Diseases involving
the skeletal system are particularly difficult to treat due to their complicated anatomical nature and the
technical difficulties involving such a complex meshwork of different cell types, particularly in the
avascular cartilage region. Despite the difficulties, targeting the skeletal system is critical for treatment
of bone lesions. The skeletal system provides support, protects visceral organs, and enables movement.
Defects in any component of this system can negatively impact theses critical functions. The idea of
creating moieties that would allow for targeted delivery of pharmaceuticals to bone tissue first came
in the late 1950s. Common skeletal disorders include osteoporosis, metabolic skeletal dysplasia, and
infectious bone disease. It is difficult to treat most diseases of the skeletal system with non-targeted
drug delivery. Visceral organs will utilize the bulk of the pharmaceutical drug, allowing very little
Int. J. Mol. Sci. 2017, 18, 1345; doi:10.3390/ijms18071345 www.mdpi.com/journal/ijms
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to reach the bone. In addition, drugs are usually excreted before a significant amount can reach the
bone. Higher doses are used to deliver small amounts of the drug into the bone; however, due to
off-target drug absorption, this often results in adverse cytotoxic effects and significantly narrows the
therapeutic options.
There are two general methods of targeted drug delivery to the skeletal system. The first involves
targeting of the entire skeletal system (Figure 1). This can be accomplished through preferential
binding to bone sites and can be done with either synthetic or biological moieties. Each of these has
unique difficulties and benefits, but this general targeting is often sufficient to treat the pathogenesis of
certain diseases including some metabolic skeletal dysplasias. The second general targeting strategy
targets drugs to specific cellular locations within the skeletal system. These targets are often either
osteoclasts, bone resorption cells, or osteoblasts, bone formation cells.
Int. J. Mol. Sci. 2017, 18, 1345 2 of 13 
 
drug, allowing very little to reach the bone. In addition, drugs are usually excreted before a significant 
amount can reach the bone. Higher doses are used to deliver small amounts of the drug into the bone; 
however, due to off-target drug absorption, this often results in adverse cytotoxic effects and 
significantly narrows the therapeutic options. 
There are t o general ethods of targeted drug delivery to the skeletal syste . The first involves 
targeting of the entire skeletal syste  (Figure 1). This can be acco plished through preferential 
binding to bone sites and can be done ith either synthetic or biological oieties. Each of these has 
unique difficulties and benefits, but this general targeting is often sufficient to treat the pathogenesis 
of certain diseases including some metabolic skeletal dysplasias. The second general targeting 
strategy targets drugs to specific cellular locations within the skeletal system. These targets are often 
either osteoclasts, bone resorption cells, or osteoblasts, bone formation cells. 
 
Figure 1. Scheme of delivery of bone-specific drug. HA, hydroxyapatite. 
Many new systems for cell-specific bone targeting have been developed in the last few years, 
increasing drug stability, improving drug solubility, and preventing degradation to enable drugs to 
reach their targets before being eliminated in blood circulation. These targeting moieties can include 
synthetic components such as tetracycline and bisphosphonates (BPs) or biological components such 
as bone marrow stem cells [1,2]. Nanoparticles (NPs) are used as drug carriers, and new methods to 
couple drugs with the NPs can provide longer half-lives, greater efficacy, and specific binding 
properties [3,4]. 
In this review, we discuss different types of targeting moieties and the most recent 
advancements in targeting moiety coupling to provide efficient delivery. We also discuss how these 
targeting systems can be used in specific or common diseases of the skeletal system.  
2. Targeting Strategies 
2.1. Bone-Targeting 
2.1.1. Bisphosphonates 
Bisphosphonates (BPs) are a family of synthetic drugs that have been widely used for several 
decades. The first publication of BPs appeared in 1969, and they have had a significant impact on the 
Figure 1. Sche e of delivery of bone-specific drug. , hydroxyapatite.
any ne syste s for cell-specific bone targeting have been developed in the last fe years,
increasing r g stability, i roving r g sol bility, an reventing egra ation to enable r gs to
reach their targets before being eli inate in bloo circulation. hese targeting oieties can inclu e
synthetic co ponents such as tetracycline and bisphosphonates (BPs) or biological co ponents such
as bone arrow stem cells [1,2]. Nanoparticles (NPs) are used as drug carriers, and new methods
to couple drugs with the NPs can provide longer half-lives, greater efficacy, and specific bin ing
properties [3,4].
In this review, we discuss different types of targeting moieties and the most recent advancements
in targeting moiety coupling to provide efficient delivery. We also discuss how these targeting systems
can be used in specific or common diseases of the skeletal system.




Bisphosphonates (BPs) are a family of synthetic drugs that have been widely used for several
decades. The first publication of BPs appeared in 1969, and they have had a significant impact on the
clinical use of bone targeting drugs [2,5]. For a long time, BPs were considered as the gold standard in
the delivery of drugs to the skeletal tissue. Their mechanism and structure are well understood [3,6]
with two terminal phosphate bonds (P-C-P), and an easily accessible central carbon whose side chains
can be manipulated. These side chains or R groups can influence drug release as well as binding
interactions. BPs have an affinity for hydroxyapatite (HA) which is a main component in hard bone
and causes preferential binding to this tissue [7]. As single agents, BPs inhibit the resorption of bone
by osteoclasts and can simultaneously enhance osteoblast differentiation [8,9], thereby promoting
bone formation. This has led to their widespread use in the treatment of osteoporosis. Limitations of
adopting bisphosphonates as targeting agents include poor bioavailability that requires high doses,
and side effects including ulcers, osteonecrosis of the jaw, and musculoskeletal pain [10,11].
Bisphosphonates to Target Proteins
Recent studies indicate that prolonged use of BP can have an inhibitory effect on osteoblasts,
thereby, negatively impacting the quality of bone mass. Jaw osteonecrosis is estimated to affect 1 in
10,000 patients treated with BPs [12].
BPs are also used in the treatment of cancers that metastasize to the bone, and the very high
doses of BPs needed to impair metastasis results in more frequent side effects [8–11]. Recently,
carboxy-terminal collagen crosslinks (CTX) was discovered as an important biomarker that can
accurately predict one’s risk of developing osteonecrosis of the jaw [12]. While this biomarker is
useful in that it provides a threshold for risk analysis of BP treatment, its necessity is indicative that
further efforts are required to reduce cytotoxicity to allow BPs to gain acceptance for use as targeting
moieties to treat skeletal diseases other than osteoporosis.
A pharmacokinetic study with Alendronate (alendronic acid; ALN) modified proteins showed
that the bone uptake of these modified proteins was, in fact, dependent on the specific modification.
The results suggested that the known affinity of ALN alone is not sufficient to ensure bone targeting as
smaller modified proteins were rapidly cleared from the circulation. When ALN modifications were
used in conjunction with PEG modification (polyethylene glycol), plasma retention time for smaller
proteins increased and more was targeted to bone [13].
Bisphosphonates to Target Nanoparticles
Great strides have been made in recent years in the targeted delivery of pharmaceuticals by way
of nanoparticles (NPs). NPs are used to improve solubility and reduce the toxicity of drugs. Their small
size allows flexibility in targeting and capability of reaching targets without inducing an immune
response. Nano particles have been prevalent in treating bone metastasis, accelerating bone formation
in osteogenesis and in conjunction with small RNAs as a vector for gene targeting and inhibition of
bone loss. Typically, bisphosphonates are chemically coupled to polymeric glycolic acids that are then
mixed with amphipathic polymers that create nanoparticles by non-covalent forces including Van der
Waals and hydrogen bonding. Proteins, RNAs, and drugs can be incorporated into these nanoparticles.
The efficiency of incorporation of compounds into NPs depends on their affinity for components of the
NP. Drugs are often trapped in the hydrophobic core of NPs while hydrophilic agents such as proteins
and RNA bind to the surface.
In a recent study, the BP risedronate was bound to HA in methoxy poly(ethylene glycol)-poly
lactic-co-glycolic acid (mPEG-PLGA) nanoparticles to treat an animal model of osteoporosis.
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This formulation reduced the toxicity of risedronate and improved its efficacy against osteoporosis by
prolonging retention in the circulation [14]. This study clearly demonstrates that BPs can target
nanoparticles to the bone. Salerno et al. developed a biodegradable compatible NP targeting
system using poly (D,L) lactide—co-glycolic acid conjugated to alendronate containing the anti-cancer
drug doxorubicin (DXR) [15]. Both prostate cancer and breast cancer metastasize to bone, causing
considerable pain. Consequently, bone-targeted drugs may be more effective against metastatic
cancer than conventional chemotherapy, with a fewer side effect. Breast cancer cell lines treated with
DXR-loaded NPs showed a strong pattern of growth inhibition (p < 0.005). When the drug-loaded
nanoparticles were administered systemically in a mouse model of bone metastasis, they were shown
to target tumors at osteolytic sites. Both free DXR and DXR coupled to nanoparticles showed significant
dose-dependent growth inhibition of tumor cell lines, although only the DXR loaded NPs were effective
at dose 1 (580 ng/mL). Both DXR loaded NPs and unloaded NPs reduced the incidence of osteolysis,
although the drug-loaded NPs were more effective [15]. It appears that the alendronate itself prevents
osteolytic lesions in bone metastasis but does not directly affect tumor cell growth.
2.1.2. Tetracyclines
Tetracyclines (TCs) are small molecular compounds that are traditionally utilized for their
antibiotic properties to treat bacterial infections. TCs are also considered very useful in the development
of targeting moieties aimed at treating diseases with skeletal manifestations particularly alveolar bone
loss. Wang et al found that TC covalently bound to polycoglycolic acid (PLGA) biopolymer NPs
enhances bone targeting of drugs due to a reaction between TC and hydroxyapatite (HA), a major
constituent of bone tissue. This coupling combines the biocompatible byproducts of the PLGA
biopolymer and the specific targeting of TC with NPs to enhance distribution and to limit cytotoxicity.
Coupling of the TC to the biopolymer was confirmed using proton nuclear magnetic resonance
(H-NMR) [16,17]. The NPs increased the amount of the osteogenic enhancing drug simvastatin (SIM)
distributed to the skeletal system. Tetracycline coupled with PLGA NPs improved overall curative
effects, which could reduce the drug dosage required for effective treatment. In addition, this system
was found to reduce the drug distribution to off-target visceral organs as measured by fluorescent
analysis [17,18].
TCs inhibit bone resorption by several mechanisms. In addition to targeting bone, TCs are
also inhibitors of collagenases. They inhibit MMPs by chelating Ca2+ and Zn2+. Sequestration of
Zn2+ prevents the conversion of procollagenase into its active form and indirectly down-regulates
collagenase gene expression. TCs diminish acid production and the secretion of lysosomal cysteine
proteinases. They also increase the number of active osteoblasts relative to inactive osteoblasts by
increasing expression of procollagen mRNA. The biological function of tetracycline is not impaired
by covalent binding to PLGA in NPs, allowing it to have continued effectiveness during bone
differentiation [19].
2.1.3. Polymeric Amino Acid Targeting
Oldberg and Heinegård found that several non-collagenous proteins that bind to HA had
repeating sequences of acidic amino acid (Asp or Glu) [20]. Sekido et al. conjugated oligopeptides
(Asp or Glu) to the fluorescent probe 9-fluorenylmethylchloroformate (Fmoc), and evaluated the
affinity of these probes for HA both in vitro and in vivo [21]. The in vitro affinity for HA was
dependent on the number of oligopeptide residue, and not on the optical isoform (L- or D-) or the
acidic amino acid species (Asp or Glu). Pharmacokinetic analysis of the probes in mice showed that
probes with six or more Asp residues were selectively delivered into the bone [21]. Thus, oligopeptide
conjugation became a candidate carrier for bone targeting. To date, many preclinical studies have been
conducted using oligopeptide conjugated drug for several diseases such as osteoporosis, infection
disease, musculoskeletal disease, and cancer.
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2.1.4. Calcium Phosphate Biomaterials
Calcium phosphates (CaP) are a main component of bone, and are consequently potentially
useful to deliver pharmaceuticals in bone. CaP scaffolds have been used to enhance healing after
a bone fracture for decades, and the ease of synthesis and natural presence of CaPs in the human
body have made such scaffolds a potential way to deliver drugs to the bone. CaP materials of several
morphological distinctions including nanorods and nanoparticles can be synthetically prepared to
include biological molecules before implantation into bone. Their high similarity to the bone mineral
makes them both biocompatible and biodegradable [20]. However, synthesis of NaP nanostructured
materials with well-defined morphology is a continuing challenge. In vivo testing of CaP vesicle-like
nanospheres has suggested promising drug delivery with limited toxicity to cells [22]. This mechanism
should play a beneficial role of CaPs in bone repair
2.2. Bone Cell-Specific Targeting
2.2.1. Osteoblast Targeting
Bone mass is regulated by a balance between bone resorption by osteoclasts derived during
hematopoiesis and bone formation by osteoblasts derived from mesenchymal stem cells [23].
Osteoblasts are found in large numbers on the outside surface of bones. An imbalance in osteoblast
and osteoclast differentiation can lead to skeletal disease [24]. There are several limitations of current
drugs that enhance bone formation. Current clinical anabolic drugs include full-length parathyroid
hormone (PTH 1–84) or its N-terminal fragment (PTH 1–34), but these drugs have severe side effects.
There is, therefore, a great need for an osteoblast-targeted drug delivery system to treat osteogenic
disorders with fewer side effects.
Gene therapy is a promising strategy for effective and safe treatment of disease that delivers
exogenous small nucleic acids such as DNA, RNA, small interfering RNA (siRNA) and micro RNA
(miRNA). Clinical success for this approach has been limited due to nucleic acid biodegradation, lack of
specificity and safe and effective delivery. The vector used to deliver nucleic acids can be either viral or
non-viral. However, substantial challenges limit viral vector use, including safety and immunogenicity
issues, promoting the development of non-viral vector delivery systems. While non-viral vectors
can have lower immunogenicity, they tend to have more frequent off target effects and are often not
biodegradable or biocompatible.
Peptides are biocompatible, they have a low immunogenic effect, are easy to synthesize and can
be produced at low cost. Peptides can be unstable during chemical modification and tend to denature
when heated. Incorporation of the targeting moiety with NPs can improve stability and direct tissue
distribution. Peptides have been used to target polyurethane (PU) nanomicelles that encapsulate small
nucleic acid by electrostatic interactions. These conjugates have excellent biocompatibility and low
toxicity making this an excellent osteoblast-targeted delivery system. An SDSSD-PU micelle NP has
been used to deliver siRNA and miRNA to osteoblasts, exerting therapeutic activity by RNAi activity.
SDSSD-PU was shown to target osteoblasts both in vivo and in vitro. Thus, SDSSD-PU NPs may be
useful to treat osteoblast dysfunction that is typical seen in many skeletal diseases, including metabolic
syndromes [25].
siRNAs play a role in the maintenance of homeostasis between osteoclasts and osteoblasts [26–28].
Concerns about the efficacy and safety of siRNA exist due to the dangers of off-target effects and the
lack of osteoblast-specific delivery systems for such siRNAs. Liang et al. identified an aptamer that
selectively recognized osteoblasts, and used this to target lipid nanoparticles containing an siRNA
against Plekho1 to both rat and human osteoblasts [27]. There was significant osteoblast uptake of the
siRNA resulting in osteoblast Plekho1 gene silencing. In vivo, the siRNA was targeted to the bone,
and bone formation was significantly improved in osteopenic rats [27].
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2.2.2. Osteoclast Targeting
The osteoclast absorbs bone tissue during growth and healing. The osteoclast is one of the most
specialized human cells. Moreover, it is in careful homeostasis with the osteoblasts maintaining and
repairing bone mass. Disturbances of the environment or regulation of osteoclast formation can affect
skeletal homeostasis and lead to severe skeletal defects. Maintenance of a healthy human skeleton is in
part dependent on mineralized bone matrix removal through bone resorption. This is accomplished
by the osteoclast through identification of damaged bones and release of proteolytic enzymes and
acidic oligopeptides. Without regulation of this function, the skeletal buildup of damaged bone matrix
can cause skeletal malformation and physical clinical manifestation. Osteoclast targeting controls the
maintenance of adequate bone mass throughout a person’s life span. Osteoclast targeting to reduce
rates of bone resorption has been utilized in the treatment of bone metastasis, Paget’s disease, and
osteoporosis [29,30].
2.2.3. Targeting with Bone Marrow Stromal Cells (BMSCs)
Bone marrow stromal cells are a part of the adult skeleton cell population with strong osteogenic
potential. The cells have high bioavailability and can be harvested readily from bone marrow of
healthy unaffected individuals [31–34]. These cells have the potential to differentiate into chondrocytes,
osteoblasts, adipocytes, etc. In the diseases that involve bone remodeling deficiencies and repair, these
cells are, therefore, potentially useful in clinical value to deliver replacement enzymes to the bone of
affected patients.
BMSC-mediated gene-directed enzyme treatment has been used in anti-tumor therapy. In one
study, a human gene was cloned from human hepatocytes and, through a constructed vector, was
targeted into human BMSCs via liposomal transport. These transfected BMSCs were found to inhibit
tumor growth by way of lymphoma cell apoptosis induction through the bystander effect when
co-cultured with Raju cells [35,36]. In addition, inhibition of cross talk in BMSCs and certain cancer
cells has been found to improve chemotherapy-induced toxicity. Pillinger et al. demonstrated this effect
when acute myeloid leukemia cells were limited in their adhesion to BMSCs via VA4ACm fibronectin
interactions, successfully limiting AML-BMSC adhesion. This shows that the drug resistance to
AML chemotherapy, which is attributed to BMSCs, can be overcome with inhibition of adhesion
in combination with standard chemotherapy agents [35]. Current efforts are focused on obtaining
BMSCs from cord blood because although they are plentiful in cord blood, transplantation from such
a source to an adult is still severely limited, although sibling matched donors have achieved greater
success [31,37,38].
3. Limitations and Perspective
The concept of bone targeting started at the beginning of last century and has tremendoushuge
potential in the treatment of skeletal disorders. Non- targeted treatments cause problems because
they deliver the majority of the drugs into visceral organs. Most problems are caused by lack of
bioavailability and biocompatibility as well as poor circulation time [39–42]. While targeting moieties
are improving drastically with the advent of NP-based delivery components and cell-specific targeting,
off-target negative side effects remain in each delivery system. In addition, the risk must be measured
individually for each patient, as these moieties can be detrimental in immunocompromised or bone
density deficient patients. Specific examples of limitations for targeting systems are shown in Table 1.
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Table 1. Examples of moieties for specific targeting in the treatment of skeletal disorders.
Targeting Moieties Targeted Tissues Specific Drugs and Moieties Primary Limitations
Bisphosphonates [12,43–45] All skeletal tissues samarium-153, pamidronate,alendronate, risedronate Cytotoxicity, osteonecrosis
Tetracycline derivatives [16–18] All skeletal tissues Estradiol Lack of specificity,gastrointestinal distress
PLGA USAuNPs [19,46,47] Cell-specific Under review Lack of understanding in mechanism,size restriction, inflammatory response
CKIP-1 [48,49] Osteoblasts CkIP-1 siRNA Off target drug deliveryand circulation time limitations
L-(asp)6, L-(glu)6 [50–52] All bone tissue CD6-TNSALP, CD8-TNSALP
Nonnative functioning,
inadequate bone delivery
Calcium Phosphates (CaP’s) [26,31] Resorption surfaces b-TCP + copolymers PLA-DX-PEG,ACP/PLLAnanofibrous scaffold
Calcium toxicity from
overabundance, osteosarcoma
SDSSD [24–27] Osteoblasts PTH 1-84, PTH 1-34 Circulation time limitations
BMSC specific aptamer [35,36] BMSCs miR-188-3p antagomir Circulation time limitations
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4. Impact and Significance of Bone Targeting on Specific Disease Burdens
4.1. Infectious Disease
4.1.1. Acidic Oligopeptide-Modified Drug for Infectious Disease
Osteomyelitis is infection and inflammation in the bone caused by acute events such as bone
fracture, surgical intervention, and bone injury. This disease can also be caused by hematogenous
spread after bacteremia. Staphylococcus aureus is the major phlogogenic bacteria in osteomyelitis.
In general, antibiotic therapy is used as a treatment for osteomyelitis for a few weeks to several months.
In severe cases, however, surgical debridement is required. Although the concentration of antibiotics
needed for treatment of bone lesions must be maintained at a very high level for a long period, this
sustained exposure increases the risk of adverse effects.
Takahashi et al. found that conjugation of quinolones to an acidic oligopeptide worked as a bone
targeting carrier in a mouse model. The selective bone delivery of quinolones conjugated to an acidic
oligopeptide was effective in treating osteomyelitis, reducing inflammatory destruction and eventual
necrosis of the healthy bone [53]. Levofloxacin (LVFX) is a fluoroquinolone antibiotic with a wide
spectrum of activity against both Gram-positive and Gram-negative bacteria. It functions by inhibiting
Type II topoisomerase enzymes. Takahashi et al. conjugated a six aspartic acid oligopeptide to LVFX
(LVFX-D6) to selectively deliver this quinolone into bone lesions and investigated pharmacokinetic
and pharmacological studies of LVFX-D6 in a mouse model of osteomyelitis [53]. After intravenous
injection of LVFX-D6 in a normal mouse, the concentration of LVFX-D6 stayed higher in bone and bone
marrow for one week when compared to that of un-modified LVFX. In all tissues except the kidney, the
bone to plasma ratio (Kp,app) of LVFX-D6 was increased when compared with that of LVFX at 2 h after
injection, indicating that LVFX-D6 was selectively delivered into bone and bone marrow. To evaluate
the pharmacological effect of LVFX-D6 and LVFX, these quinolones were administered into a mouse
model of osteomyelitis inoculated with Staphylococcus aureus into tibia bone. LVFX-D6 continued to
suppress the proliferation of the bacteria for at least for 6 days while a colony-forming unit in LVFX
treated mice was almost recovered to the levels of untreated mice by 6 days after injection.
4.1.2. BP-Modified Drug for Infectious Disease
Since BPs have a high affinity for the calcium ion of HA, BP-modified antibiotic agents
for osteomyelitis have been examined in a pre-clinical study [47–49]. PLGA-PEG NPs have
been used for drug delivery due to the merits of the PLGA-PEG moiety previously discussed.
A 4,5-Dimethylthiazol-2-yl)-2,5-diphenyltettrazolium bromidefor assay or MTT assay showed that
antibiotic-loaded PLGA-PEG-ALN micelles were not more cytotoxic than blank micelles in rBMSCs
L02 cells, indicating that vancomycin-loaded PLGA-PEG-ALN micelles would be safe in the treatment
of osteomyelitis. Antibacterial effects of this bone targeting micelle were also tested in vitro by using
Staphylococcus aureus. Although the minimum inhibitory concentration (MIC) of free vancomycin was
2 µg/mL, the MIC of vancomycin-loaded PLGA-PEG-ALN micelles was higher, at 16 µg/mL. Authors
explained that free drug concentration in the medium did not reach the MIC when the concentration
in the conjugate was lower than 16 µg/mL. However, this micelle formulation did inhibit the activity
of Staphylococcus aureus in the in vivo model of osteomyelitis [46,47].
Ferreira et al. developed long-circulating and ALN-conjugated liposomes containing
99mtechnetium (99mTc)-radiolabeled ceftizoxime to improve the efficiency of drug delivery into
the infectious site of bone [43]. Ceftizoxime is a third-generation cephalosporin which has wide
broad spectrum activity. Previously, authors have developed pH-sensitive liposome containing
99mTc-radiolabeled ceftizoxime to diagnose infection disease in bone lesions. However, uptake of
this liposome containing 99mTc-radiolabeled ceftizoxime in the infectious area was not higher than
free 99mTc-radiolabeled ceftizoxime. Scintigraphic image test showed that ALN-decorated liposome
contacting 99mTc-radiolabeled ceftizoxime increased target-to-non-target ratio in tibia compared with
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the non-decorated formulation or the non-long circulating formulation in an osteomyelitis animal
model. Target-to-non-target ratio in the tibias of the osteomyelitis model was also higher than that
in an aseptic inflammation model or healthy animal model. Thus, the authors suggested that this
bone-targeting liposome containing 99mTc-radiolabeled ceftizoxime showed high affinity in infectious
foci of bone lesions and would be useful for diagnosis and treatment of osteomyelitis [43].
4.2. Osteoporosis
4.2.1. Acidic Oligopeptide-Modified Drug for Osteoporosis
Osteoporosis is a metabolic disorder of bone strength characterized by low bone mass and
micro-architectural deterioration of bone tissue. This disease leads to increasing bone fragility and
fracture risk. Pathophysiology of osteoporosis is based on the weakening of bone bridge formation
due to relative increasing bone resorption against ossification. Osteoporosis is a serious problem
particularly for women, and a major cause of decreasing bone mineral density in this disorder is
acute hypo secretion of estrogen with the menopause. Hormone-related therapy for osteoporosis,
i.e., estrogen, maintains bone mineral density. However, this therapy can increase the risk of breast
cancer, endometrial cancer, blood clots and heart disease. Therefore, development of bone-targeting
therapy for osteoporosis is required not only to enhance the treatment effect but also to reduce the risk
of such adverse effects.
Sekido et al. and Yokogawa et al. performed a pharmacokinetic analysis of estradiol (E2)
conjugated with L-Asp-hexapeptide at either the 17β-position (E2-17 βD6) or the 3-position (E2-3D6)
via succinate ester [44,45]. After a single intravenous administration of 3.7 µmol/kg E2, E2-17 βD6
or E2-3D6 in normal mice, total clearance (CLtot) of both oligopeptide-conjugated forms of E2 was
significantly decreased compared with that of free E2, and apparent tissue to plasma concentration
ratio (Kp,app) of E2-17 βD6 or E2-3D6 in femur was markedly higher than that of E2 while Kp,app of
both oligopeptide-conjugated E2 in other tissues was unchanged or slightly decreased. These results
indicate that oligopeptide-conjugated E2 could be selectively delivered to bone lesions. The affinity
of E2-17 βD6 or E2-3D6 to human estrogen receptor (ERα and ERβ) was 10,000-fold or 100-fold less
than that of E2, respectively [44,45]. Pharmacological analysis showed administration of E2-17 βD6 or
E2-3D6 in ovariectomized murine model improved bone mineral density without increasing uterine
weight although both bone mineral density and uterine weight were elevated after injection of E2.
Therefore, acidic oligopeptide-conjugated E2 would be effectively delivered into the bone lesion and
reduce the risk of side effect of E2.
4.2.2. BP-Modified Drug for Osteoporosis
BP-conjugated prodrugs of prostaglandin E2 [54] and 17β-estradiol [43,46,55] were developed in
preclinical studies. These studies showed that different types of linkages affected pharmacokinetics and
pharmacological effects of the BP-conjugated drug. As new targeting techniques for bone, preparation
of BP conjugated to polymers, NPs or other materials are under investigation for an anti-osteoporotic
drug [56,57]. Katsumi et al. reported that PEG-conjugated-ALN improves bioavailability and safety
since oral bioavailability of free ALN is low and it causes mucosal damage as an adverse effect [57].
Intrapulmonary administration of PEG-conjugated-ALN in rats did not induce pulmonary mucosal
damage or affect drug absorption when compared to free ALN. Intrapulmonary administration of
PEG-conjugated-ALN in an osteoporotic rat model slowed decrease of growth plate to a similar level
achieved with ALN. The effects were evaluated on bone tissue from the right tibia of female rats with
treatment groups including intrapulmonary administration of alendronate at a dosage of 2 mg/kg and
intrapulmonary administration of PEG alendronate at a dosage of 2 mg/kg. Groups were evaluated
after eight weeks, and both the width of the growth plate and the density of the bone structure were
reduced, with the intrapulmonary administration of PEG alendronate preventing or reversing the
decreases in the width of the bone plate and the density of the bone structure.
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For the future, linkage of BP to imaging agents within NPs and polymers would enable bone
monitoring and diagnosis for osteoporosis [58].
4.3. Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease. Inflammation from the
synovial cell and endothelial cell activation leads to cartilage and bone destruction by causing the
excessive production of cytokines, chemokines and other factors including TNF-a, IL-6, and IL-1.
Recently, several reports showed high-mobility group box 1 (HMGB1) level was elevated in serum and
synovial fluid of RA patients [50,59]. HMGB1 binds to a receptor for advanced glycation end products
(RAGE) [60,61] that activates intracellular signaling and produces inflammatory cytokines [43].
Takahashi et al. conjugated an acidic oligopeptide to endogenous secretory RAGE (esRAGE) as
a decoy receptor. They determined the tissue distribution of this bone-targeting endogenous secretory
receptor and its effect on RA in an animal model [56]. After administration of acidic oligopeptide
conjugated-esRAGE (D6-esRAGE, 1 mg/kg) to an RA model mouse, they showed that D6-esRAGE
was retained in bone lesions for at least a week while esRAGE was not detectable after 72 h. Weekly
administration of D6-esRAGE suppressed serum level of inflammatory cytokines such as TNF-a,
IL-1, and IL-6, and cartilage and bone destruction was less pronounced than in esRAGE treated
RA mice. D6-esRAGE showed a histopathological score of less than 1.5 in the synovial lesion,
less than 1.0 in cartilage destruction and 0.9 in bone destruction. The untreated controls showed
histopathological scores of 2.75 in synovial lesions, 2.0 in cartilage destruction and 2.25 in bone
destruction. D6-esRAGE and esRAGE significantly decreased plasma levels of TNF-a, IL-1, and IL-6,
as measured by an enzyme-linked immunosorbent assy (ELISA) (p < 0.05) however D6-esRAGE was
more effective than free esRAGE [53].
4.4. Metabolic Skeletal Dysplasia
Metabolic disorders are caused by an inborn error of metabolism due to an inherited gene
mutation. Some metabolic disorders occur from birth; others only become apparent in later life.
The result of the mutated or deficient gene is typically a build of- material that should be degraded and
a lack of material that is necessary for the metabolic pathway to function correctly, usually caused by
enzyme deficiency [51,62–67]. Often these metabolic disorders will have a skeletal component. One of
the most common genetic metabolic disorders that lead to skeletal dysplasia is Mucopolysaccharidosis
(MPS). Although this group of disorders can be caused by the mutation of different genes and have
different modes of heritability, all forms of MPS result in a deficiency of specific enzymes necessary to
degrade GAG proteins. The lack of the enzyme leads to unique clinical phenotypes, in which one of the
most recognizable features is stunned long bone growth and consequent abnormal skeletal dysplasia.
Enhancement of the effects of the deficient enzyme treatment involves targeting the enzyme
directly to the bone. Attempts at treating skeletal dysplasia in MPS involving non-bone targeting
delivery has failed to produce skeletal improvements due to the short circulation time and its
excretion and uptake in non-target visceral organs. Enzyme replacement therapy (ERT) for
Mucopolysaccharidosis type IVA (MPS IVA) provides a greater effect on bone pathology in MPS
IVA mice when coupled with the acidic oligopeptide tag although early treatment is recommended for
the greater success [64].
Nishioka et al. found that tissue-nonspecific alkaline phosphate (TNSALP) tagged with an acidic
oligopeptide could improve hypophosphatasia when this enzyme was deficient in vivo. This method
resulted in a 30-fold higher affinity for HA relative to the affinity of the untagged enzyme [51].
This bone targeting ALP enzyme showed a substantial clinical improvement in bone mineral density,
prolonged life span, and activity of daily living of patients with hypophosphatasia and the modified
enzyme was approved by the Federal Drugs Agency (FDA) to treat hypophosphatasia [52].
Gene therapy, which would provide a permeant and one-time solution, could be effective if
administered before the onset of skeletal dysplasia; however, a vector system that would allow the
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delivery is not yet available in a clinical setting. Gene therapy is expected to be a one-time permanent
treatment, with the protein of interest continuously secreted from transduced cells. We have already
engineered an adenoassociated virus (AAV2) vector to target gene delivery to the bone by integrating
multiple copies of a short acidic amino acid peptide into the gene vector capsid. To increase the vector
affinity for HA, eight aspartic acidic residues (D8) were inserted immediately after the N-terminal
region of the VP2 capsid protein in the packing plasmid. The modified vector was generated with
physical titers and transduction efficiencies comparable to the unmodified vector. After intravenous
administration of this modified vector capsid into the MPS IVA model mouse, the bone-targeting
vector showed significantly higher HA affinity and vector genome copies in bone compared with
the unmodified vector. Expression of N-acetyl-galactosamine-6-sulfate (GALNS) in bone was also
significantly elevated compared with enzyme levels in bone of mice transduced with the unmodified
vector [68,69].
5. Future Directions
Bone-targeting systems to deliver siRNA have been designed, and their effects in the treatment
of osteoporosis have been examined in a preclinical study [48,70,71]. It is difficult to deliver siRNA
into targeted cells since the water soluble siRNA cannot cross the hydrophobic plasma membrane.
D8 bone-affinity polymeric NPs packaged with siRNA for semaphorin 4d was administered into
osteoporotic mouse model via weekly intravenous injection. After administration, the number of
active osteoblasts at the bone surface was significantly increased, and bone mass density (BMD) and
bone volume/tissue volume were improved compared with those in untreated mice [70].
Manipulation of dysregulated miRNA in osteoclasts has been found to facilitate microRNA
modulators with great success. Dang et al. found that when miRNA modulators are coupled with
D-(Asp)s, antogomiR-148a is enriched, resulting in the downregulation of osteoclast forming miR0148a
in osteoclasts [49]. This leads to reduced bone resorption and attenuated deterioration of trabecular
structure in model osteoporotic mice. While this specific approach has not been attempted in human
subjects, its success in vivo with limited off-target effects shows promise.
In the future, combining bone-targeting with gene therapy could significantly improve efficacy in
the treatment of bone diseases. However, type of vector, route of administration and adverse effects
are yet to be determined.
6. Conclusions
Although the idea of bone-targeted delivery of pharmaceuticals in skeletal disorders has been
studied for decades, the identification of carrier systems capable of increasing efficacy, reducing the
off-target effect, minimizing delivery to visceral organs, and allowing increased solubility, leading
to maintenance of bone integrity, have only recently been examined in detail. The evaluation of
these therapies needs to include risk as well as cost/benefit assessments. These factors along with
problems of bioavailability remain as challenges for this type of delivery system. Nevertheless, the
advancement of some targeting moieties into clinically approved drugs and advances in gene therapy
offer the prospects of developing successful one-time treatments to correct bone defects in metabolic
skeletal dysplasia.
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